Arsenale Bioyards Wants to Slash Biomanufacturing Costs by 90%—Investors Just Bet $10M on It
The startup secures funding to make large-scale biomanufacturing cost-effective with AI-driven fermentation.
Feb 28, 2025
[Canva]
Arsenale Bioyards, a neo-industrial startup redefining the future of scalable biomanufacturing, has raised $10 million in seed funding. The round was co-led by Planet A and byFounders, with participation from CDP Ventures, Acequia Capital, Plug N Play, Grey Silo Ventures, and industrial family offices.
The funding will accelerate Arsenale’s mission to transform the $200 billion biomanufacturing market, making large-scale biological production cost-effective and sustainable. By integrating AI-driven software with modular industrial bioreactors, the company aims to optimize fermentation processes and dramatically speed up the transition from lab-scale experiments to full-scale industrial production.
Neo-Industrial Biomanufacturing: A New Approach to Scaling Biology
Arsenale Bioyards is pioneering a "neo-industrial" approach—co-designing with nature to create a circular and efficient manufacturing system. The company’s precision fermentation technology leverages microorganisms like yeast and bacteria to produce proteins and other bio-based materials. While widely used in pharmaceuticals, its application in industries like food and cosmetics has been hindered by high costs.
Arsenale’s end-to-end AI-driven platform aims to overcome this challenge, cutting production costs and time-to-market by up to 90%. Central to this transformation are Bioyards, modular bio-reactor networks that scale out rather than up, breaking from the traditional approach of building ever-larger fermenters.
"At Planet A, we saw Arsenale’s potential early on—this is a fundamental rethink of how biomanufacturing scales," said Christoph Gras, Co-Founder & General Partner at Planet A Ventures. "By making production cost-competitive and standardized, Arsenale turns biomanufacturing into an investable asset class while enabling industries to move away from animal- and petrochemical-derived products at scale."
AI-Driven Biomanufacturing: Smarter, Faster, More Efficient
Arsenale Bioyards is rethinking the way biomanufacturing operates, shifting from traditional trial-and-error experimentation to a data-driven, AI-powered model. The company collects and analyzes real-time bioprocess data, using AI to guide experiment design and predict large-scale performance.
By designing its own bioreactors, Arsenale ensures seamless integration with machine learning models, allowing for:
Faster optimization of fermentation conditions
Automation of scaling processes
Significant reduction in both operational (OPEX) and capital (CAPEX) expenses
"Arsenale is not just imagining the bioeconomy of the future—we are building it today," said Massimo Portincaso, CEO and Co-Founder of Arsenale Bioyards. "This funding reinforces our ability to drive measurable change and build a generative, biology-driven industrial paradigm."
Scaling Up: From Pilot Facility to Industry-Wide Adoption
Arsenale Bioyards is already demonstrating its capabilities with a fully operational pilot site in Pordenone, equipped with:
1,000L of precision fermentation capacity
Two advanced 500L bioreactors
A suite of modular precision fermentation units with industry-first real-time sensing capabilities
This infrastructure positions Arsenale for rapid commercialization in sectors like food, cosmetics, and biomaterials, where sustainable, bio-based alternatives are in high demand.
A World-Class Team Driving Innovation
Arsenale’s leadership team brings together deep expertise in biotech, AI, and industrial-scale manufacturing:
Massimo Portincaso (CEO & Co-Founder): Former BCG partner and biotech entrepreneur, previously co-founded and exited Officinae Bio.
Gordana Djordjevic (CSO): Former scientific leader at Perfect Day, Zymergen, Synthetic Genomics, BP, and BASF, with 25+ years of experience scaling industrial fermentation.
Niels Lynge Agerbæk (CTO): Former VP at Zymergen, GM at Xellia Pharmaceuticals US, and Director at Novo Nordisk, leading Arsenale’s technical implementation.
Matteo Zanotto (CIO): PhD in AI and deep learning, spearheading Arsenale’s machine learning and algorithmic innovations.
Arnaud Legris (COO): Engineer and former BCG consultant, ensuring smooth operational execution.
With this funding, Arsenale Bioyards is poised to redefine the future of biomanufacturing—making sustainable, bio-based production a reality at industrial scale.


















